Spots Global Cancer Trial Database for sintilimab
Every month we try and update this database with for sintilimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | NCT05251662 | Intrahepatic Ch... | Sintilimab IBI305 GEMOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. | NCT04220944 | Hepatic Carcino... | Sintilimab Microwave Ablat... TACE | 18 Years - 80 Years | Shanghai Zhongshan Hospital | |
| Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC | NCT03629925 | Squamous NSCLC | Sintilimab Gemcitabine Cisplatin Placebo Carboplatin | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC | NCT05029973 | Hepatocellular ... | HAIC Sintilimab Bevacizumab Bio... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer | NCT03745170 | Gastric Cancer | Sintilimab Oxaliplatin Capecitabine placebo | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer | NCT05306847 | Carcinoma, Non-... | Sintilimab Anlotinib | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma. | NCT05207735 | Cholangiocarcin... | Sintilimab | 18 Years - 75 Years | Henan Cancer Hospital | |
| Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer | NCT04202601 | Advanced Gastri... | Sintilimab IBI310 | 18 Years - | Peking University | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | NCT05214339 | Unresectable He... Hepatocellular ... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | NCT06308939 | Metastatic Brea... | Eribulin Sintilimab | 18 Years - | Zhejiang Cancer Hospital | |
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | NCT06308939 | Metastatic Brea... | Eribulin Sintilimab | 18 Years - | Zhejiang Cancer Hospital | |
| SRS Sequential Sindilimab in Brain Metastasis of NSLSC | NCT04180501 | NSCLC Stage IV Brain Metastase... SRS Sintilimab | SRS sequential ... | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC | NCT03607539 | Lung Neoplasms | Sintilimab Pemetrexed Platinum Placebos | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer | NCT03989336 | Ovarian Cancer | Manganese Chlor... nab-paclitaxel Platinum chemot... Sintilimab | 18 Years - 70 Years | Chinese PLA General Hospital | |
| Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free) | NCT05835245 | Advanced Intrah... | Cryoablation Sintilimab Lenvatinib | 18 Years - | Fudan University | |
| Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC | NCT05992584 | Hepatocellular ... | Lenvatinib, sin... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma | NCT05201859 | Nasopharyngeal ... | Sintilimab Capecitabine | 18 Years - 70 Years | Sun Yat-sen University | |
| Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer | NCT05088967 | Non-small Cell ... | IBI110 sintilimab | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer | NCT05890742 | MSI-H | Sintilimab IBI310&Sintilim... Radical surgery | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer | NCT04982939 | Gastric Cancer Perioperative Sintilimab | Sintilimab S-1 Oxaliplatin | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma | NCT04312204 | Primary Pulmona... Lung Cancer | Sintilimab comb... | 18 Years - 75 Years | Guangzhou Institute of Respiratory Disease | |
| Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer | NCT06204094 | Locally Advance... | node-sparing sh... Sintilimab Capecitabine Oxaliplatin TME surgery watch and wait | 18 Years - 75 Years | Jinhua Central Hospital | |
| A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC | NCT04672369 | Advanced Lung C... | IBI939 Sintilimab | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC | NCT04682249 | ICC | Systemic Chemot... Sintilimab Apatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) | NCT04167293 | Hepatocellular ... | stereotactic bo... Sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | NCT03794440 | Hepatocellular ... | Sintilimab IBI305 Sorafenib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer | NCT04213170 | Brain Metastase... Non Small Cell ... Sintilimab Bevacizumab | sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC | NCT04718909 | Hepatocellular ... | Regorafenib + s... Regorafenib | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC | NCT04840290 | Non Small Cell ... | Biological: Sin... | 18 Years - 70 Years | Tang-Du Hospital | |
| A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy | NCT04044222 | Classic Hodgkin... | Sintilimab Carboplatin Etoposide Ifosfamide Placebo Carboplatin Etoposide Ifosfamide | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors | NCT03758001 | Advanced Solid ... | IBI101 IBI101 Sintilimab | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | NCT05026593 | SCLC | Carboplatin Cisplatin Etoposide Sintilimab IBI110 | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma | NCT05617430 | Hepatocellular ... | HAIC Sintilimab Bevacizumab Bio... | 18 Years - | Wuhan Union Hospital, China | |
| Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer | NCT04840758 | Multiple Primar... | Stereotactic Ab... Sintilimab | 18 Years - 75 Years | The First Affiliated Hospital of Xiamen University | |
| SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC | NCT04106180 | NSCLC Stage IV | GM-CSF Sintilimab SBRT | 18 Years - | Fudan University | |
| Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer | NCT04202601 | Advanced Gastri... | Sintilimab IBI310 | 18 Years - | Peking University | |
| cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria | NCT04842565 | Hepatocellular ... | Sintilimab TACE | 20 Years - 75 Years | Fudan University | |
| Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer | NCT06347198 | Metastatic Colo... | Fruquintinib Sintilimab Inulin | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) | NCT04072107 | Nasopharyngeal ... | sintilimab Capecitabine | 18 Years - 65 Years | Sun Yat-sen University | |
| Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer | NCT05450029 | Rectal Cancer | Sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors | NCT05527821 | Unresectable Ad... Biliary Tract T... | Surufatinib Sintilimab Short course ra... | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients | NCT03812549 | Stage IV NSCLC | Sintilimab stereotactic bo... Low Dose Radiot... | 18 Years - 70 Years | Sichuan University | |
| Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） | NCT04459611 | Non-small Cell ... | sintilimab pemetrexed Carboplatin albumin-bound p... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | NCT04371796 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Sintilimab inje... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study | NCT04796025 | Hepatocellular ... | Sintilimab; Bev... | 18 Years - 69 Years | Sun Yat-sen University | |
| HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT | NCT04618367 | Carcinoma, Hepa... Liver Neoplasms Sintilimab Portal Vein Tum... | Hepatic arteria... Lenvatinib Sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer | NCT05170581 | Non-small Cell ... | Sintilimab Comb... | 18 Years - 75 Years | The Second Affiliated Hospital of Shandong First Medical University | |
| Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | NCT03765775 | Carcinoma Non-small Cell ... Lung Neoplasm | Sintilimab Anlotinib Hydro... | 18 Years - 75 Years | First Hospital of Shijiazhuang City | |
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | NCT06308939 | Metastatic Brea... | Eribulin Sintilimab | 18 Years - | Zhejiang Cancer Hospital | |
| Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer | NCT04973293 | Lung Neoplasm M... | sintilimab bevacizumab | 18 Years - 75 Years | Ruijin Hospital | |
| Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) | NCT04271813 | Colorectal Canc... Immunotherapy Anlotinib Sintilimab Chemo-free Ther... First-line Trea... | Anlotinib plus ... | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer | NCT04202601 | Advanced Gastri... | Sintilimab IBI310 | 18 Years - | Peking University | |
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | NCT05251662 | Intrahepatic Ch... | Sintilimab IBI305 GEMOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | NCT03802240 | Non-Squamous No... | Sintilimab IBI305 Pemetrexed Cisplatin Placebo1 Placebo2 | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | NCT03802240 | Non-Squamous No... | Sintilimab IBI305 Pemetrexed Cisplatin Placebo1 Placebo2 | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study | NCT03798743 | Non-small Cell ... | Sintilimab Comb... | 18 Years - 75 Years | Hunan Province Tumor Hospital | |
| Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis | NCT05204173 | Gastric Cancer ... Peritoneal Meta... | sintilimab, pac... | 18 Years - | Ruijin Hospital | |
| Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients | NCT03228836 | Effect of Drugs | Sintilimab | 18 Years - 70 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma | NCT05625737 | Stomach Neoplas... | Fruquintinib Sintilimab | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma | NCT06220552 | Recurrent Gliob... | Sintilimab Low-dose Radiot... | 18 Years - | Fifth Affiliated Hospital, Sun Yat-Sen University | |
| Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | NCT06342167 | Locally Advance... Sintilimab Radiotherapy Concurrent Chem... Immunonutrition | Radiotherapy Programmed Cell... Immunonutrition... | 18 Years - 80 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma | NCT04961515 | Primary Central... | Orelabrutinib Orelabrutinib Sintilimab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC | NCT04055792 | Extensive Disea... | Sintilimab | 18 Years - | Henan Cancer Hospital | |
| Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma | NCT06413342 | Esophageal Canc... Chemoradiothera... Sintilimab Immunotherapy Elderly Patient... | Sintilimab | 70 Years - 85 Years | Zhejiang Cancer Hospital | |
| TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Patients With Advanced Hepatocellular Carcinoma (TASK-02) | NCT04954794 | Hepatocellular ... | Sintilimab TACE | 18 Years - | Fudan University | |
| The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution. | NCT06029829 | Hepatocellular ... | Sintilimab | 18 Years - 75 Years | China Three Gorges University, Yichang, China | |
| Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer | NCT04906044 | Tislelizumab Locally Advance... Total Neoadjuva... PD-1 | Sintilimab | 18 Years - 80 Years | The First Hospital of Jilin University | |
| Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer | NCT06221462 | Carcinoma, Non-... | Sintilimab Anlotinib | 18 Years - 75 Years | Ningbo No.2 Hospital | |
| Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC | NCT05244213 | Non-small Cell ... EGFR Activating... | Sintilimab Carboplatin Nab paclitaxel | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | NCT04371796 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-small-cell ... | Sintilimab inje... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer | NCT03745170 | Gastric Cancer | Sintilimab Oxaliplatin Capecitabine placebo | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma | NCT04297280 | Hepatocellular ... | Sintilimab TACE | 18 Years - | Fudan University | |
| Sintilimab in FH-deficient Renal Cell Carcinoma | NCT04146831 | Renal Cell Carc... FH-deficient Sintilimab | Sintilimab | 18 Years - | West China Hospital | |
| Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer | NCT05088967 | Non-small Cell ... | IBI110 sintilimab | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC | NCT05400070 | Sintilimab Lung Cancer Anlotinib Chemotherapy | Neoadjuvant the... | 18 Years - 72 Years | Tang-Du Hospital | |
| Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | NCT04263870 | Gastroesophagea... Stomach Adenoca... Locally Advance... Metastatic Gast... | sintilimab | 18 Years - 75 Years | Sichuan University | |
| Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer | NCT05450029 | Rectal Cancer | Sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | NCT06333561 | Hepatocellular ... Lenvatinib PD-1 Inhibitor Hepatic Arteria... | Hepatic arteria... Lenvatinib Tislelizumab Toripalimab Sintilimab Camrelizumab | 18 Years - 75 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
